About Nurix Therapeutics, Inc.
https://www.nurixtx.comNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.
CEO
Arthur T. Sands
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 135
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
FMR LLC
Shares:8.89M
Value:$169.22M
BLACKROCK INC.
Shares:6.82M
Value:$129.85M
BLACKROCK, INC.
Shares:6.76M
Value:$128.76M
Summary
Showing Top 3 of 193
About Nurix Therapeutics, Inc.
https://www.nurixtx.comNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.89M ▼ | $94.28M ▲ | $-86.42M ▼ | -1.09K% ▼ | $-1.03 ▼ | $-81.42M ▼ |
| Q2-2025 | $44.06M ▲ | $14.28M ▲ | $-43.46M ▲ | -98.66% ▲ | $-0.52 ▲ | $-46.08M ▲ |
| Q1-2025 | $18.45M ▲ | $11.65M ▲ | $-56.35M ▲ | -305.38% ▲ | $-0.67 ▲ | $-60.51M ▲ |
| Q4-2024 | $13.28M ▲ | $10.72M ▼ | $-58.55M ▼ | -440.75% ▼ | $-0.75 ▼ | $-63.41M ▼ |
| Q3-2024 | $12.59M | $11.72M | $-48.96M | -388.91% | $-0.67 | $-52.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $428.83M ▼ | $522.47M ▼ | $150.22M ▲ | $372.25M ▼ |
| Q2-2025 | $485.78M ▼ | $591.55M ▼ | $143.95M ▲ | $447.6M ▼ |
| Q1-2025 | $549.68M ▼ | $615.04M ▼ | $134.13M ▼ | $480.92M ▼ |
| Q4-2024 | $609.58M ▲ | $669.34M ▲ | $142.35M ▲ | $526.99M ▲ |
| Q3-2024 | $448.05M | $513.6M | $136.74M | $376.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-86.42M ▼ | $-57.38M ▲ | $50.48M ▼ | $1.16M ▲ | $-5.75M ▼ | $-60.1M ▲ |
| Q2-2025 | $-43.46M ▲ | $-63.16M ▼ | $71.5M ▲ | $6K ▼ | $8.34M ▲ | $-65.84M ▼ |
| Q1-2025 | $-56.35M ▲ | $-61.09M ▼ | $25.53M ▲ | $1.47M ▼ | $-34.08M ▼ | $-64.57M ▼ |
| Q4-2024 | $-58.55M ▼ | $-48.75M ▼ | $-140.82M ▼ | $200.52M ▲ | $10.95M ▲ | $-50.86M ▼ |
| Q3-2024 | $-48.96M | $-42.18M | $-21.34M | $45.77M | $-17.75M | $-44.52M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $10.00M ▲ | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ |
 License Revenue | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
CEO
Arthur T. Sands
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 135
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
FMR LLC
Shares:8.89M
Value:$169.22M
BLACKROCK INC.
Shares:6.82M
Value:$129.85M
BLACKROCK, INC.
Shares:6.76M
Value:$128.76M
Summary
Showing Top 3 of 193